## SUPPLEMENTARY MATERIALS

# Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.

Hindocha, C<sup>1\*</sup>., Freeman, T.P<sup>1,2</sup>., Grabski, M<sup>1,3</sup>., Stroud, J.B<sup>1</sup>., Crudgington, H<sup>1</sup>., Davies, A.C.<sup>1</sup>., Das, R.K<sup>1</sup>., Lawn, W<sup>1</sup>., Morgan, C.J.A<sup>1,4</sup>., Curran, H.V.<sup>1</sup>

<sup>1</sup>Clinical Psychopharmacology Unit, University College London, WC1E 7HB

<sup>2</sup>National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8BB, United Kingdom.

<sup>3</sup>School of Experimental Psychology, University of Bristol, 12a Priory Road, BS81TU, Bristol.


<sup>4</sup>Psychopharmacology and Addiction Research Centre, University of Exeter, UK

#### Running Head: CANNABIDIOL FOR TOBACCO WITHDRAWAL

**Correspondence to:** Chandni Hindocha, Clinical Psychopharmacology Unit, University College London, 1-19 Torrington Place, London, WC1E 7HB. Email: <u>c.hindocha@ucl.ac.uk</u>

# **Supplementary Method**

#### **Participant recruitment**



Supplementary Figure 1: flow diagram for study recruitment and assessments. The final sample included 30 participants who completed all three sessions.

### Procedure

Supplementary table 1: Schedule of assessments on the satiated and abstinent sessions.

SATIATED		ABSTINENT	
TIME		TIME	
0	Arrival	0	Arrival
12	MPSS QSU [1]	5	MPSS QSU HR BP [1]
30	Cigarette	10	Drug administration
35	MPSS QSU [2]	70	MPSS QSU HR BP [2]
60	Visual Probe	130	MPSS QSU HR BP [3]
68	PRT	190	Visual Probe
75	MPSS QSU [3]	198	PRT
-	-	200	MPSS QSU [4]

## **Supplementary Results**

#### Time since last smoked

There was a significant main effect of abstinence (F(1,29)=3289.03, p<.001,  $\eta^2 p=.99$ ) where on the satiated session, participants last smoked M: 0.41 (SD: 0.40) hours previously, in comparison to abstinent. There was no main effect of drug (F(1,29)=0.18, p=.675,  $\eta^2 p=.006$ ). Participants last smoked M: 10.97 (SD:0.96) hours previously on the CBD session and M:11.03 (SD:0.95) on the PBO session.

#### CO

There was a significant main effect of abstinence (F(1,29)=167.83 p<.001,  $\eta^2 p=.84$ ) which shows CO was higher in the satiated condition (M: 17.73 ppm SD: 6.63) than in the abstinent conditions. There was no main effect of drug (F(1,29)=6.13, p=.019,  $\eta^2 p=.17$ ) where CO was 4.27ppm (SD:2.23) for CBD and 4.17 (SD:2.69) for PBO. Thus abstinence was biologically verified.

### MPSS

#### Amount of time spent with urge

Pre-drug time spent with urges was significantly greater under abstinent than satiated sessions F(1,29)=27.96, p<.001,  $\eta^2 p=.49$  suggesting abstinence increased the amount of time spent with urges to smoke. There was no different between CBD and PBO, pre-drug administration (p=0.536; JZS BF in support of the null= 5.86). To investigate if CBD attenuated craving in comparison to placebo on abstinent sessions, we conducted an ANOVA that showed a main effect of time (F(3,87)=8.65, p<.001,  $\eta^2 p=.23$ ) which showed that time spent with urges decreased from T1 (3.17, 95% CI 2.79-3.64) to T3 (2.40, 95% CI 1.97-2.82), and increased from T3 to T4 (2.80, 95% CI 2.38-3.22). However there was no effect of drug (p=1.00; JZS BF in support of the null= 7.08) There was no drug x time interaction F(2, 68)=.25, p=.81,  $\eta^2 p=0.00$ ).

#### **Strength of urges**

Pre-drug strength of urges was significantly greater under abstinent than satiated sessions F(1,29)=26.26, p<.001,  $\eta^2 p=.48$  suggesting abstinence increased the strength of urges. There was no different between CBD and PBO, pre drug administration (p=0.879; JZS BF in support of the null= 6.99). To investigate if CBD attenuated craving in comparison to placebo on abstinent sessions, we conducted an ANOVA that showed a main effect of time (F(3,87)=4.33, p=.007,  $\eta^2 p=.13$ ) which showed that time spent with urges decreased significantly from T1 (2.92, 95% CI 2.58-3.25) to T2 (2.40, 95% CI 2.02-2.78), and increased from T2 to T3 (2.48, 95% CI 2.10-2.87) and T4 (2.73, 95% CI 2.31-3.16). However there was no effect of drug (p=.61; JZS BF in support of the null= 6.20) There was no drug x time interaction F(3, 87)=0.65, p=0.58,  $\eta^2 p=0.02$ ).

### Side effects

*Strong Drug effect:* There was no main effect of drug (F(1,29)=.80, p=.379,  $\eta^2 p=.03$ ) confirmed by Bayesian analysis (JZS BF: 4.82), time (F(2,58)=.37 p=.695,  $\eta^2 p=.01$ ), or drug x time interaction (F(2,58)=2.18, p=.123,  $\eta^2 p=.07$ ).

*Good Drug effect:* There was no main effect of drug (F(1,29)=.10, p=.922,  $\eta^2 p=.00$ ) confirmed by Bayesian analysis (JZS BF:7.04), time (F(2,58)=2.76, p=.072,  $\eta^2 p=.09$ ), or drug x time interaction (F(2,58)=2.18, p=.123,  $\eta^2 p=.07$ ).

*Willing to take drug again:* There was no main effect of drug (F(1,29)=2.35, p=.136,  $\eta^2 p=.08$ ) confirmed by Bayesian analysis (JZS BF: 2.35), time (F(2,58)=0.42, p=.661,  $\eta^2 p=.01$ , or drug x time interaction (F(2,58)=1.12, p=.306,  $\eta^2 p=.040$ ).

*Like drug effect:* There was no main effect of drug (F(1,29)=.01, p=.947,  $\eta^2 p=.00$ ) confirmed by Bayesian analysis (JZS BF: 7.06) or drug x time interaction (F(2,58)=.03, p=.968,  $\eta^2 p=.00$ ). There was a main effect of time (F(2,58)=3.53, p=.036,  $\eta^2 p=.11$ ) which showed liking decreased over time.

*I have a stomach ache:* There was no main effect of drug (F(1,29)=.00, p=.957,  $\eta^2 p=.00$ ) confirmed by Bayesian analysis (JZS BF:7.07), time (F(2,58)=.01, p=.988,  $\eta p^2=.000$ ), or drug x time interaction (F(2,58)=1.44, p=.245,  $\eta^2 p=.05$ ).

*I have a headache:* There was a drug x time interaction (F(2,58)=3.17, p=.049,  $\eta^2 p=.099$ ). Exploration of the interaction showed no significant pairwise comparisons. There was no main effect of drug (F(1,29)=.04, p=.839,  $\eta^2 p=.00$ ) confirmed by Bayesian analysis (JZS BF:6.93), or time (F(2,58)=.80, p=.456,  $\eta^2 p=.03$ ).